Epidemiological studies have provided compelling evidence that multiple sclerosis (MS) is a
rare complication of infection with the Epstein–Barr virus (EBV), a herpesvirus that infects …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Resolving conflict of interest The Joint Task Force on Practice Parameters (JTFPP) is
committed to ensuring that all guidelines are based on the best scientific evidence at the …

Severe immune-related adverse events (irAEs) occur in up to 60% of patients with
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

Abstract Digital Spatial Profiling (DSP) is a method for highly multiplex spatial profiling of
proteins or RNAs suitable for use on formalin-fixed, paraffin-embedded (FFPE) samples. The …

With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a double-stranded DNA
virus that is ubiquitous in 90–95% of the population as a gamma herpesvirus. It exists in two …